Zhu W - Search Results

1

Correction: Do women with high-risk HPV E6/E7 mRNA test positivity and NILM cytology need colposcopy?

Liu Y, Jin X, Gong Y, Ma Y, Du B, Yang L, Wang Y, Zhu W. Liu Y, et al. Among authors: zhu w. Infect Agent Cancer. 2023 Dec 11;18(1):83. doi: 10.1186/s13027-023-00554-3. Infect Agent Cancer. 2023. PMID: 38082329 Free PMC article. No abstract available.

2

Do women with high-risk HPV E6/E7 mRNA test positivity and NILM cytology need colposcopy?

Liu Y, Jin X, Gong Y, Ma Y, Du B, Yang L, Wang Y, Zhu W. Liu Y, et al. Among authors: zhu w. Infect Agent Cancer. 2023 Sep 29;18(1):54. doi: 10.1186/s13027-023-00531-w. Infect Agent Cancer. 2023. PMID: 37773080 Free PMC article.

3

Performance of Aptima HPV E6/E7 mRNA Test for Detection of Cervical Lesions in a Large Chinese Population.

Yang Z, Zhu W, Liu Y, Chen X. Yang Z, et al. Among authors: zhu w. Iran J Public Health. 2022 Nov;51(11):2549-2554. doi: 10.18502/ijph.v51i11.11172. Iran J Public Health. 2022. PMID: 36561247 Free PMC article.

4

ERBB3 mediates the PI3K/AKT/mTOR pathway to alter the epithelial‑mesenchymal transition in cervical cancer and predict immunity filtration outcome.

Yang X, Zhu W. Yang X, et al. Among authors: zhu w. Exp Ther Med. 2023 Feb 15;25(4):146. doi: 10.3892/etm.2023.11845. eCollection 2023 Apr. Exp Ther Med. 2023. PMID: 36911370 Free PMC article.

5

Synthesis of Au@MOF core-shell hybrids for enhanced photodynamic/photothermal therapy.

Cai X, Zhao Y, Wang L, Hu M, Wu Z, Liu L, Zhu W, Pei R. Cai X, et al. Among authors: zhu w. J Mater Chem B. 2021 Sep 7;9(33):6646-6657. doi: 10.1039/d1tb00800e. Epub 2021 Aug 9. J Mater Chem B. 2021. PMID: 34369551

6

Effects of Different Treatment Methods on the Clinical and Urodynamic State of Perimenopausal Women with Stress Urinary Incontinence.

Liu L, Zhang Y, Gong J, Chen X, Wu H, Zhu W. Liu L, et al. Among authors: zhu w. Iran J Public Health. 2018 Aug;47(8):1090-1097. Iran J Public Health. 2018. PMID: 30186780 Free PMC article.

7

Long non-coding RNA LINC01627 is a prognostic risk factor for epithelial ovarian cancer.

Shen X, Zhu W. Shen X, et al. Among authors: zhu w. Oncol Lett. 2019 Sep;18(3):2861-2868. doi: 10.3892/ol.2019.10661. Epub 2019 Jul 24. Oncol Lett. 2019. PMID: 31452765 Free PMC article.

8

MicroRNA-196a promotes cell proliferation and inhibits apoptosis in human ovarian cancer by directly targeting DDX3 and regulating the PTEN/PI3K/AKT signaling pathway.

Ni J, Chen L, Ling L, Wu M, Ren Q, Zhu W. Ni J, et al. Among authors: zhu w. Mol Med Rep. 2020 Aug;22(2):1277-1284. doi: 10.3892/mmr.2020.11236. Epub 2020 Jun 15. Mol Med Rep. 2020. PMID: 32626994 Free PMC article.

9

RGD-Conjugated Resveratrol HSA Nanoparticles as a Novel Delivery System in Ovarian Cancer Therapy.

Long Q, Zhu W, Guo L, Pu L. Long Q, et al. Among authors: zhu w. Drug Des Devel Ther. 2020 Dec 30;14:5747-5756. doi: 10.2147/DDDT.S248950. eCollection 2020. Drug Des Devel Ther. 2020. PMID: 33408463 Free PMC article.

10

MicroRNA-301a Promotes Cell Proliferation and Resistance to Apoptosis through PTEN/PI3K/Akt Signaling Pathway in Human Ovarian Cancer.

Ni J, Chen Y, Fei B, Zhu Y, Du Y, Liu L, Guo L, Zhu W. Ni J, et al. Among authors: zhu w, zhu y. Gynecol Obstet Invest. 2021;86(1-2):108-116. doi: 10.1159/000513070. Epub 2021 Feb 17. Gynecol Obstet Invest. 2021. PMID: 33596588

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

19,263 results

Search Page

Filters